Você procurou por: trough (Inglês - Maltês)

trough
hawt

plasma trough
l-inqas

trough fev1 (ml)
l-anqas livell tal-fev1 (ml)

trough concentrations has
konċentrazzjonijiet baxxi

trough and peak fev1:
l-anqas u l-ogħla fev1:

test (trough value)
test (valur minimu)

cmin (trough, g/l)
cmin (minimu, g/l)

trough concentration following once weekly dosing:
l- inqas konċentrazzjoni wara dożaġġ ta ’ darba fil- ġimgħa:

trough level of at least 4 – 6 g/ l
kull 2 – 4 ġimgħat biex jinkiseb livell minimu ta ’ igg ta ’ mill- inqas 4 – 6 g/ l

nintedanib trough concentrations remained stable for more than one year.
il-konċentrazzjonijiet minimi ta' nintedanib baqgħu stabbli għal aktar minn sena.

the target for trough concentrations was 10-20 ng/ml.
il- mira għall-konċentrazzjonijiet l-aktar baxxi kienet ta’ 10-20 ng/ml.

the risk may be increased as the trough sirolimus level increases.
ir-riskju jista’ jiżdied jekk il-livelli l-aktar baxxi ta’ sirolimus jogħlew.

the relationship between tacrolimus trough levels (c24) and systemic
ir- relazzjoni bejn il- livelli ‘ trough ’ ta ’ tacrolimus (c24) u l - espożizzjoni sistemika (auc0- 24) għal advagraf tixbaћ ħafna lil dik ta ’ prograf.

plasma trough concentrations of boceprevir were decreased when administered with efavirenz.
il-konċentrazzjonijiet l-iktar baxxi tal-plasma ta’ boceprevir tnaqqsu meta mogħtija ma’ efavirenz.

change from baseline in trough fev1 last observation carried forward (locf)
bidla mil-linja bażi fl-inqas livell tal-fev1 last observation carried forward (locf)

every 3-4 weeks to obtain igg trough level above 5g/l
kull 3-4 ġimgħat biex jinkiseb livell minimu ta’ igc ta’ aktar minn 5 g/l

10 hepatotoxicity has been reported, the risk may increase as the trough sirolimus level increases.
epatossiċità ġiet rapportata, ir- riskju jista ’ jiżdied kif il- livelli l- aktar baxxi ta ’ sirolimus jiżdiedu.

also, when switching between different tablet strengths, verification of trough concentrations is recommended.
il-verifika tal-konċentrazzjonijiet l-aktar baxxi hija rakkomandata wkoll meta jkun hemm bdil bejn qawwiet differenti tal-pilloli.

table 1: trough fev1 (ml) at week 12 and week 24 (primary endpoint)
tabella 1: il-livell minimu tal-fev1 (ml) fil-Ġimgħa 12 u fil-Ġimgħa 24 (endpoint primarju)

parameter cmax (peak, g/l) cmin (trough, g/l) t½ (days)
parametru cmax (massimu, g/ l) cmin (minimu, g/ l) t½ (jiem)